There are two well-described syndromes caused by tumor production of parathyroid hormone-related peptide (PTHrP), namely osteolytic bone disease associated with breast cancer and humoral hypercalcemia of malignancy (HHM) that occurs with or without bone metastasis. Both syndromes have been shown experimentally to be inhibited by neutralizing antibodies to PTHrP. In a search for small-molecule inhibitors of PTHrP production or effects, we have identified guanine-nucleotide analogs as compounds that inhibit PTHrP expression by human tumor cells associated with these syndromes. We show in nude athymic murine models that these compounds reduce PTHrP-mediated osteolytic lesions associated with metastatic human breast-cancer cells as well as the degree of hypercalcemia caused by excessive PTHrP production by a squamous-cell carcinoma of the lung. These results suggest that the PTHrP gene promoter may be a suitable target for treating the skeletal effects of malignancy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC151806 | PMC |
| http://dx.doi.org/10.1172/JCI11936 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CCN3: lactational bone booster.
Cell Biosci
December 2024
USDA/ARS Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, USA.
Mammalian reproduction requires that nursing mothers transfer large amounts of calcium to their offspring through milk. Meeting this demand requires the activation of a brain-breast-bone circuit during lactation that coordinates changes in systemic hormones, dietary calcium intake, skeletal turnover, and calcium transport into milk. Classically, increased bone resorption via increased parathyroid hormone-related protein and low estrogen levels is the main source of calcium for milk production during lactation.
View Article and Find Full Text PDFDiffuse Large B-Cell Lymphoma Presenting With Hypercalcemia.
Cureus
November 2024
Internal Medicine, Icahn School of Medicine at Mount Sinai, Queens Hospital Center, New York, USA.
Hypercalcemia is a common metabolic complication associated with malignancies, particularly in solid tumors, such as lung and breast cancers. However, its occurrence in hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL), is rare. The pathophysiology of hypercalcemia in lymphomas is often related to the secretion of parathyroid hormone (PTH)-related peptide (PTHrP).
View Article and Find Full Text PDFCutaneous Squamous Cell Carcinoma Producing Granulocyte Colony-stimulating Factor and Parathyroid Hormone-related Protein: A Case Report and Literature Review.
Intern Med
December 2024
Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan.
We herein report a case of cutaneous squamous cell carcinoma (SCC) characterized by paraneoplastic hypercalcemia-leukocytosis syndrome. The patient presented with systemic symptoms, including anorexia, a fever, and a tumoral lesion on the upper arm. Laboratory test results revealed hypercalcemia and leukocytosis.
View Article and Find Full Text PDFTiming of resting zone parathyroid hormone-related protein expression affects maintenance of the growth plate during secondary ossification: a computational study.
Biomech Model Mechanobiol
November 2024
Department of Biosystems Science, Institute for Life and Medical Sciences, Kyoto University, 53 Shogoin-Kawahara-Cho, Sakyo-Ku, Kyoto, 606-8507, Japan.
Secondary ossification and maintenance of the growth plate are crucial aspects of long bone formation. Parathyroid hormone-related protein (PTHrP) has been implicated as a key factor in maintaining the growth plate, and studies suggest that PTHrP expression in the resting zone is closely related with formation of the secondary ossification center (SOC). However, details of the relationship between resting zone PTHrP expression and preservation of the growth plate remain unclear.
View Article and Find Full Text PDFD-limonene suppresses RANKL-induced osteoclast differentiation and promotes osteoblast activity in-vitro.
Biosci Biotechnol Biochem
November 2024
Agri-pharmacy Group, School of Biomedical Sciences, Faculty of Health, University of Plymouth, Plymouth, UK.
Article Synopsis
- Osteoporosis treatments are usually implemented after fractures occur, so finding preventative methods to lower fracture risk is important.
- D-limonene, a natural compound found in citrus fruits, has shown potential in promoting bone health by enhancing osteoblast activity and suppressing osteoclast formation, largely due to its effects on NFκB.
- The study indicates that limonene not only supports the development of bone-forming cells but also decreases factors that lead to bone loss, suggesting it could be a useful supplement alongside existing osteoporosis treatments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!